title: Metadherin is a prognostic predictor of hepatocellular carcinoma after curative hepatectomy.
abstract: OBJECTIVE
  The prognosis after surgical resection of hepatocellular carcinoma (HCC) remains poor because of a high rate of recurrence. Thus, it is crucial to identify patients with a high risk of recurrence after curative hepatectomy and to develop more effective and targeted treatment strategies to improve disease outcomes. In this study, we investigated the roles of metadherin (MTDH) in the prognosis of HCC.
  
  
  METHODS
  We investigated MTDH expression using immunohistochemistry in tumor tissue microarrays of 288 primary HCC patients who underwent curative surgical resection.
  
  
  RESULTS
  High MTDH expression was observed in 138 of the 288 HCC cases (47.9%). High MTDH expression was associated with a younger age (p<0.001), higher Edmondson grade (p<0.001), microvascular invasion (p<0.001), higher American Joint Committee on Cancer T stage (p=0.001), and higher α-fetoprotein level (p=0.003). Multivariate analyses revealed that high MTDH expression (p=0.014), higher Barcelona-Clinic Liver Cancer (BCLC) stage (p<0.001), and Edmondson grade III (p=0.042) were independent predictors of shorter disease-free survival (DFS). Higher BCLC stage (p<0.001) and Edmondson grade III (p=0.047) were also independent predictors of shorter disease-specific survival.
  
  
  CONCLUSIONS
  High MTDH expression may be a prognostic predictor of shorter DFS in HCC patients after curative hepatectomy.
authors.affiliation: Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors.forename: Soomin
authors.initials: S
authors.lastname: Ahn
authors.forename: Jiyeon
authors.initials: J
authors.lastname: Hyeon
authors.forename: Cheol-Keun
authors.initials: CK
authors.lastname: Park
keywords: Hepatocellular carcinoma; Metadherin; Survival
references.citation: Oncol Rep. 2012 Jun;27(6):2073-9
references.pmid: 22470125
references.citation: Cancer Res. 2006 Feb 1;66(3):1509-16
references.pmid: 16452207
references.citation: Cancer Cell. 2004 Apr;5(4):365-74
references.pmid: 15093543
references.citation: Hepatology. 1995 Sep;22(3):983-93
references.pmid: 7657307
references.citation: Cancer Cell. 2009 Jan 6;15(1):9-20
references.pmid: 19111877
references.citation: J Clin Invest. 2009 Mar;119(3):465-77
references.pmid: 19221438
references.citation: Gene. 2005 Jun 20;353(1):8-15
references.pmid: 15927426
references.citation: Clin Cancer Res. 2009 Sep 15;15(18):5615-20
references.pmid: 19723648
references.citation: Gastroenterology. 2007 Jun;132(7):2557-76
references.pmid: 17570226
references.citation: Int J Colorectal Dis. 2010 Oct;25(10):1201-9
references.pmid: 20625905
references.citation: Clin Cancer Res. 2011 Dec 1;17(23):7294-302
references.pmid: 21976539
references.citation: Ann Surg Oncol. 2006 Nov;13(11):1474-84
references.pmid: 17009164
references.citation: Oncogene. 2007 Dec 6;26(55):7647-55
references.pmid: 17563745
references.citation: Carcinogenesis. 2009 May;30(5):894-901
references.pmid: 19304953
references.citation: Semin Liver Dis. 2005;25(2):181-200
references.pmid: 15918147
references.citation: Oncogene. 2008 Feb 14;27(8):1114-21
references.pmid: 17704808
references.citation: Semin Liver Dis. 1999;19(3):329-38
references.pmid: 10518312
references.citation: Cancer. 1954 May;7(3):462-503
references.pmid: 13160935
references.citation: N Engl J Med. 2008 Nov 6;359(19):1995-2004
references.pmid: 18923165
references.citation: Hepatology. 2011 Sep 2;54(3):757-9
references.pmid: 21793027